source
- Avalyn Pharma launches $300M IPO, selling 16.5 million shares at $18 eachAvalyn Pharma, a Boston-based biotech, announced an initial public offering that aims to raise roughly $300 million. The company will sell more than 16.5 million shares at $18 per share and is set…
- Analysts zero in on three Bristol Myers programs as company gears up for multiple data readouts through 2026Analysts are closely watching Bristol Myers Squibb's pipeline, focusing on three key programs that could drive growth in the coming years. Wall Street expects a flurry of data readouts, with at le…